Idm Pharma Inc

Idm Pharma — Investor Presentation (January 2007)

38 slides from Idm Pharma's investor presentation, Jan 8, 2007

  1. Slide 1: Corporate Presentation - January 8, 2007

    DRAFT CONFIDENTIAL Corporate Presentation - January 8, 2007 Exhibit 99.1

  2. Slide 2: Safe Harbor Statement

    This presentation includes forward-looking statements that reflect management's current views of future events such as statements about the expected timing of milestone events, the potential therapeutic benefits of and expected commercial plans for our product candidates, and our strategic goals. Ac

  3. Slide 3: Mission

    Mission IDM is focused on the development of innovative products that activate the immune system to treat cancer. Goal: To cure while caring for quality of life

  4. Slide 4: Highlights

    Highlights Lead product completed Phase III in Osteosarcoma NDA Filed October 25th 2006 MAA Filed November 3rd 2006 Potential for other indications in oncology 4 additional products in clinical development Product and equity partnership with Sanofi-Aventis Headquarters in Irvine, CA

  5. Slide 5: Corporate partners

    Corporate partners sanofi aventis MEDAREX

  6. Slide 6: Product candidates

    Product candidates Destroy cancer cells by activating innate immunity Prevent tumor recurrence by triggering a specific adaptive immune response Two product lines in oncology with the goals to:

  7. Slide 7: Product candidate pipeline

    To prevent tumor recurrence Candidate Indication Phase I Phase II Phase III Marketing Rights Ph III trial completed Junovan(tm) Osteosarcoma IDM Ph II/III Bexidem(r) Bladder cancer IDM Ph II Uvidem(r) Melanoma Ph II EP-2101 NSC Lung Cancer IDM Ph I/ II Colorectal cancer IDM (1) (1) Cambridge Laborat

  8. Slide 8: First line of products to destroy cancer cells

    To prevent tumor recurrence First line of products to destroy cancer cells Candidate Indication Phase I Phase II Phase III Marketing Rights Ph III trial completed Junovan(tm) Osteosarcoma IDM Ph II/III Bexidem(r) Bladder cancer IDM Ph II Uvidem(r) Melanoma Ph II EP-2101 NSC Lung Cancer IDM Ph I/ II

  9. Slide 9: Junovan: Completed Phase III in osteosarcoma

    Junovan: Completed Phase III in osteosarcoma Fully synthetic compound Targeting osteosarcoma, bone cancer in adolescents Orphan drug status in EU & U.S. JUNOVAN (L-MTP-PE) is currently limited for clinical investigational use only: its safety and efficacy have not been reviewed or approved for comme

  10. Slide 10: Muramyl Tripeptide-Phosphatidyl Ethanolamine (MTP-PE)

    Muramyl Tripeptide-Phosphatidyl Ethanolamine (MTP-PE) MTP PE Junovan chemical entity

  11. Slide 11: Junovan formulation: Liposomal MTP-PE

    Electron microscopy picture of a multilamellar liposome The lipophilic molecule MTP- PE is intercalated in the lipid bilayers at a MTP-PE phospholipid ratio of 1:250 Junovan formulation: Liposomal MTP-PE Nardin A. et al, Current Cancer Drug Targets, 6:561-571, 2006 L-MTP-PE

  12. Slide 12: Junovan activates anti-tumor function of macrophages through NOD2 receptor

    Junovan activates anti-tumor function of macrophages through NOD2 receptor NOD2 Plasma membrane Cytosol MDP Macrophage TNFa IL- 1 IL- 8 IL- 6 Adapted from Strober W., Nature Rev Immunol, 6:9-20, 2006 L-MTP- PE L-MTP- PE L-MTP- PE L-MTP- PE Signaling pathway of NOD2 intracellular receptor 1. Junovan

  13. Slide 13: MTP-PE Encapsulated in Liposomes Protects against Spontaneous Metastases

    MTP-PE Encapsulated in Liposomes Protects against Spontaneous Metastases 0 10 20 30 40 50 60 70 80 90 100 0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200 L-MTP-PE L-MDP Vehicle Control Days After Footpad Implantation i.v. treatment s A metastasis forming tumor was surgically

  14. Slide 14: L-MTP-PE Biodistribution at 5 hours

    L-MTP-PE Biodistribution at 5hours spleen lungs nasopharynx liver Murray et al., J. Clin. Oncol., 1989

  15. Slide 15: Macrophage ability to kill a tumor cell

    Macrophage ability to kill a tumor cell 1 hr 30 min macrophage tumor cell 6 hr tumor cell debris

  16. Slide 16: Junovan: Phase II results in relapsed osteosarcoma with lung metastases

    Junovan (L-MTP-PE) as single agent injected IV after surgical resection of lung metastases Limited side effects Junovan: Phase II results in relapsed osteosarcoma with lung metastases 0 10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 Disease-Free Surviv

  17. Slide 17: Junovan Induces the Infiltration of Lung Metastases by Inflammatory Macrophages

    Junovan Induces the Infiltration of Lung Metastases by Inflammatory Macrophages Immunohisto- chemical staining of lung lesions before (A) and after (B) liposomal MTP- PE therapy. Staining with anti- MRP-14 reveals brown to black inflammatory macrophages. Kleinerman et al., Cancer Immunol. Immunother

  18. Slide 18: Junovan: Phase III osteosarcoma results

    Junovan: Phase III osteosarcoma results Overall Survival Years Proportion surviving 0 1 2 3 4 5 6 0.0 0.2 0.4 0.6 0.8 1.0 - - Junovan + Junovan Disease-Free Survival Years Proportion surviving relapse free 0 1 2 3 4 5 6 0.0 0.2 0.4 0.6 0.8 1.0 - - Junovan + Junovan In 678 patients with non-metastati

  19. Slide 19: Junovan: Product status

    Junovan: Product status NDA filed in October 2006 with FDA and November 2006 with EMAE, launch anticipated in 2007 Exclusive worldwide sales and marketing rights in U.S. and major part of Europe Orphan drug designation provides 7 year marketing exclusivity in the U.S. and 10 years in Europe upon app

  20. Slide 20: Other potential cancer indications

    Other potential cancer indications Junovan's mechanism of action provides a rationale for potential benefit in treating patients with lung metastases regardless of the site of the primary tumor Cancer originating in kidney, breast, ovarian, prostate, colon and melanoma are susceptible to metastasize

  21. Slide 21: Junovan market potential in osteosarcoma

    Junovan market potential in osteosarcoma Approximately 1,000 new patients per year in North America and 1,000 in EU Increase in survival: 10% at 6 years (from 67.5% to 77.2%)* Osteosarcoma develops in children and young adolescents; if cured, they can hope to have a normal life expectancy Pricing an

  22. Slide 22: Bexidem

    Thiounn N. et al, J. Urology 168:2373-76, 2002 Bexidem Product containing activated macrophages Targeting bladder cancer Addresses unmet medical needs Tumor removal, local chemo and BCG therapy of limited benefit Phase I/II clinical trial completed Tumor occurrences for 17 patients decreased to 8 fr

  23. Slide 23: Bexidem: Product status

    Bexidem: Product status Completed enrollment of 138 patients in Phase II in EU FDA Special Protocol Assessment for Phase II/III in US Interim data analysis in safety expected mid 2007 Exclusive worldwide sales and marketing rights Opportunity to partner with large pharma More than 60,000 new cases o

  24. Slide 24: Second line of products to prevent tumor recurrence

    To prevent tumor recurrence Candidate Indication Phase I Phase II Phase III Marketing Rights Ph III trial completed Junovan(tm) Osteosarcoma IDM Ph II/III Bexidem(r) Bladder cancer IDM Ph II Uvidem(r) Melanoma Ph II EP-2101 NSC Lung Cancer IDM Ph I/ II Colorectal cancer IDM (1) (1) Cambridge Laborat

  25. Slide 25: Dendritic cells induce T cell responses

    Dendritic cells induce T cell responses Lymphoid organ B B T T T T T T Lymphocyte activation MATURE Dendritic cells T Peripheral tissue Pathogen

  26. Slide 26: IDM Cell Drug therapy - an efficient process

    IDM Cell Drug therapy - an efficient process Outpatient apheresis Apheresis product Ship Elutriation Purified dendritic cells or MAK 20 doses from one apheresis Ship Outpatient treatment Culture with cytokines 7 Days Proprietary IDM Process Wash & concentrate and freeze cells

  27. Slide 27: Uvidem: Partnered with Sanofi-Aventis

    Uvidem: Partnered with Sanofi-Aventis Cell Drug: Dendritic cells loaded with melanoma cell lysates Targeting melanoma - the most deadly form of skin cancer Addresses unmet medical need Phase I/II trial completed 15 patients with metastatic melanoma stage III and IV Product well-tolerated with no maj

  28. Slide 28: Uvidem: Product status

    Uvidem: Product status Phase II data in late stage patients presented at ASCO, May 2005 Phase II trial in earlier stage patients ongoing in U.S. Phase II combination trial in EU started in 2005 Close to 60,000 new melanoma diagnosed in the U.S. per year* Partnered with Sanofi-Aventis * American Canc

  29. Slide 29: Key partnership with Sanofi-Aventis

    Key partnership with Sanofi-Aventis Sanofi-Aventis has an option for exclusive worldwide rights on selected products IDM receives milestones payments and reimbursement of clinical expenses Manufacturing at IDM and transfer price including royalties First product selected: Uvidem, in Phase II for tre

  30. Slide 30: Collidem and EP-2101

    Collidem: Dendritic cells + peptides Targeting colorectal cancer - the third most common cause of death from cancer in the U.S. Phase I/II clinical trial in the U.S. to evaluate immune and clinical responses in addition to safety in patients with metastatic colorectal cancer Enrollment of patients c

  31. Slide 31: Multi-epitope product candidate pipeline

    Multi-epitope product candidate pipeline Colorectal (Collidem) Ovarian Prostate Breast Lung (EP2101)

  32. Slide 32: Financial data

    Financial data Year Ended 9 months ended Statement of Operations December 31, 2005 September 30, 2006 (Thousands except loss per share) Total revenues $ 8,540 $ 8,328 Loss from operations (40,044) (16,230) Net loss (39,209) (17,322) Loss per share $3.84 $1.30 Balance Sheet As of December 31, 2005 As

  33. Slide 33: Management team

    Management team Herve Duchesne de Lamotte, MBA VP, Finance and General Manager France MIT, AT Kearney Bonnie Mills, PhD VP, Clinical Operations and General Manager, U.S. Nexell, Baxter Jean-Loup Romet-Lemonne, MD Founder & CEO Harvard University, Transfusion Merieux Innovation James Bender, PhD Dire

  34. Slide 34: Experienced non-executive board members

    Experienced non-executive board members Robert Beck, MD VP of Fox Chase Cancer Center Jean Deleage, PhD Managing general partner, Alta Partners Don Drakeman, JD, PhD Former CEO of Medarex Inc. Mike Grey CEO of SGX Pharmaceuticals, Inc. Sylvie Gregoire, Pharm D Former Biogen Inc. Executive Executive

  35. Slide 35: 2006 announced milestones

    Junovan - FDA/EMEA NDA filing Bexidem - Special Protocol Assessment for Phase II/III Uvidem - complete enrollment of melanoma Phase II trial in Europe Uvidem - complete enrollment of melanoma Phase II in U.S. Collidem - Phase I/II trial results in colorectal cancer EP-2101 - complete Phase II trial

  36. Slide 36: Expected milestones

    Junovan - FDA and EMAE marketing approval Junovan - Overall survival data publication Uvidem - Phase II data submitted for presentation at ASCO Uvidem - New Phase II in association with chemotherapy initiated in melonoma EP2101 - Phase II data in NSCLC submitted at ASCO Bexidem - Phase II safety dat

  37. Slide 37: Summary

    Summary Lung EP2101 Candidate Indication Phase I Phase II Phase III Ph III trial completed Junovan(tm) Osteosarcoma Ph II/III Bexidem(r) Bladder cancer Ph II Uvidem(r) Melanoma Ph I/II Collidem(r) Colorectal cancer Ph I/II EP-2101 NSC Lung Cancer

  38. Slide 38: www.idm-pharma.com

    DRAFT CONFIDENTIAL www.idm-pharma.com NASDAQ: IDMI

IDM Pharma — Investor Presentation (January 2007) on 6ix